Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlling type I error rate for fast track drug development programmes.

Weichung J Shih1, Peter Ouyang, Hui Quan

  • 1University of Medicine & Dentistry of New Jersey, 335 George Street, Liberty Plaza Room 3456, New Brunswick, NJ 08903, USA. shihwj@umdnj.edu

Statistics in Medicine
|February 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiological characteristics of serum small dense low-density lipoprotein cholesterol: From 2017 to 2019 in Chengdu adults, China.

Medicine·2026
Same author

Development and validation of a nomogram model for predicting negative/indeterminate HIV-1 antibody confirmation: a strategy to streamline the diagnostic pathway.

BMC medical informatics and decision making·2026
Same author

Haplotype-resolved long-read sequencing reveals parent-of-origin effects of tandem-repeat variation in autism spectrum disorder.

Science bulletin·2026
Same author

Analytical techniques for laboratory testing of HIV: a systematic review.

Journal of microbiological methods·2026
Same author

Sequential Parallel Comparison Design for Assessing Induction, Maintenance, Long-Term, and Other Treatment Effects on a Binary Endpoint.

Statistics in medicine·2026
Same author

Epidemiological characteristics and antibiotic resistance of pathogens in urinary tract infection in Chengdu 2019-2023, China.

BMC microbiology·2026
Same journal

Latent Class Log-Linear Models for Estimating Diagnostic Test Accuracy Without a Gold Standard: A Simulation Study.

Statistics in medicine·2026
Same journal

Interpretable Bayesian Modeling for Multireader Multicase Studies: Addressing Overdispersion and Limited Sample Size in Diagnostic Enhancement Evaluation.

Statistics in medicine·2026
Same journal

Adaptive Sequential Multiple Hypotheses Testing for Concomitant Vaccine Safety Surveillance.

Statistics in medicine·2026
Same journal

Novel Distance Regression for Repeated Outcomes With Missing Data: Applications to Longitudinal and Crossover Studies of Microbiome Beta-Diversity.

Statistics in medicine·2026
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
See all related articles

The Fast Track Drug Development program expedites new drugs for serious conditions. This study addresses statistical challenges, proposing methods to control type I errors in drug approval processes.

Area of Science:

  • Pharmacology
  • Drug Development
  • Biostatistics

Background:

  • The FDA Modernization Act of 1997 established the Fast Track Drug Development program.
  • Fast Track Drug Development programs aim to expedite novel therapeutics for unmet medical needs.
  • Existing programs have successfully delivered treatments for AIDS, cancer, and osteoporosis.

Purpose of the Study:

  • To discuss statistical issues arising from Fast Track Drug Development programs.
  • To introduce the concepts of 'conditional approval' and 'final approval' type I errors.
  • To propose statistical methodologies for managing these type I errors during drug review.

Main Methods:

  • Conceptual analysis of type I errors in drug approval.
  • Development of statistical methods for error control.

Related Experiment Videos

  • Application to new drug submission processes.

    • Main Results:

    • Identification of two distinct type I error types: conditional and final approval.
    • Proposal of statistical frameworks to manage these errors.
    • Potential for enhanced regulatory decision-making.

    Conclusions:

    • Statistical rigor is crucial for Fast Track Drug Development programs.
    • Controlling type I errors ensures drug safety and efficacy.
    • Proposed methods can improve the reliability of expedited drug approvals.